KCTD17

KCTD17 is a substrate-adaptor for Cullin3-RING E3 ubiquitin ligase complexes that directs the ubiquitin-dependent proteasomal degradation of diverse substrates to regulate ciliogenesis, hepatic lipid metabolism, adipogenesis, liver fibrosis, and tumorigenesis. It assembles as a closed pentameric BTB-domain ring that forms 5:5 heterodecamers with Cul3 and recruits substrates including trichoplein (initiating ciliogenesis by inactivating Aurora-A), PHLPP2 (prolonging Akt signaling to promote hepatic steatosis), OGA (stabilizing ChREBP to drive lipogenic gene expression), CHOP (modulating adipogenesis), LZTR1 (stabilizing Ras to promote hepatocellular carcinoma), and Zbtb7b (suppressing SERPINA3 to drive liver fibrosis) (PMID:25270598, PMID:28963344, PMID:28859855, PMID:36402191, PMID:36868076, PMID:39098817, PMID:40744994). Independent of its E3 ligase adaptor function, KCTD17 binds Gβγ subunits through its C-terminus to attenuate Gβγ-mediated sensitization of adenylyl cyclase 5, thereby shaping GPCR-cAMP signaling (PMID:36736897). KCTD17 shares partially redundant roles with the paralogous adaptors KCTD2 and KCTD5 in controlling cell growth and Gβ1 protein levels (PMID:38732215).

1. 2014 High

   The first substrate and biological function of KCTD17 were identified: it serves as the Cul3 adaptor that ubiquitylates trichoplein at mother centrioles, triggering trichoplein destruction and allowing axoneme extension during ciliogenesis.

   Evidence Global E3 ligase screen, siRNA, ubiquitylation assays, non-ubiquitylatable trichoplein mutant rescue in RPE1 cells

   PMID:25270598

   Open questions at the time

   • Structural basis for trichoplein recognition by KCTD17 not determined
   • Whether KCTD17 has substrates beyond trichoplein was unknown
   • Signal that activates KCTD17-mediated trichoplein degradation at cell-cycle exit not identified
2. 2016 High

   Epistasis analysis placed KCTD17 downstream of Ndel1 in the trichoplein–Aurora-A ciliary suppression pathway, establishing the signaling hierarchy controlling ciliogenesis in proliferating versus quiescent cells.

   Evidence siRNA coknockdown epistasis in mammalian cells and Ndel1-hypomorphic mouse model

   PMID:26880200

   Open questions at the time

   • Direct mechanism by which Ndel1 regulates KCTD17 activity not elucidated
   • Whether this pathway operates in all ciliated cell types remains untested
3. 2017 High

   The structural basis of KCTD17 assembly was resolved: its BTB domain forms a closed pentameric ring that binds Cul3 in an unusual 5:5 heterodecameric architecture lacking the canonical 3-box motif, explaining how this adaptor oligomerizes and engages the ubiquitin ligase machinery.

   Evidence X-ray crystallography, SAXS, and size-exclusion chromatography

   PMID:28963344

   Open questions at the time

   • No structure of the KCTD17–substrate complex available
   • How the pentameric ring accommodates substrate geometry is unclear
4. 2017 High

   KCTD17 was linked to hepatic metabolism: glucagon/PKA-dependent phosphorylation of PHLPP2 creates a KCTD17-binding degron, and KCTD17-mediated PHLPP2 destruction prolongs insulin/Akt signaling to drive hepatic lipogenesis and steatosis, revealing the first metabolic substrate of KCTD17.

   Evidence Mass spectrometry phosphosite and interactome mapping, shRNA in primary hepatocytes and obese mice, CRISPR KO hepatoma cells

   PMID:28859855

   Open questions at the time

   • Whether KCTD17 expression itself is nutritionally regulated was not addressed
   • Relative contribution of KCTD17 versus other PHLPP2 degradation pathways in vivo not quantified
5. 2017 Medium

   Functional conservation between mammalian KCTD17 and Drosophila Insomniac was demonstrated: mouse KCTD17 forms Cul3 complexes and traffics to synapses, and paralogous KCTD2/5 rescue sleep loss in fly inc mutants, suggesting a conserved neural role for this adaptor family.

   Evidence Biochemical complementation, in vivo sleep rescue in Drosophila, neuronal imaging

   PMID:28558011

   Open questions at the time

   • KCTD17-specific rescue in the Drosophila sleep assay was not individually demonstrated
   • Neural substrates of KCTD17 in the mammalian brain remain unidentified
   • Whether KCTD17 has non-redundant roles in sleep regulation is untested
6. 2022 High

   A second metabolic substrate was identified: KCTD17, induced by Srebp1c under obesity, degrades OGA, leading to stabilized ChREBP protein and enhanced lipogenic gene expression, establishing KCTD17 as a feed-forward amplifier of hepatic lipogenesis.

   Evidence AAV-CRISPR hepatocyte-specific KO mice, ASO treatment, Kctd17/Oga double-KO epistasis, transcriptomics

   PMID:36402191

   Open questions at the time

   • Whether KCTD17-mediated OGA degradation affects O-GlcNAcylation of targets beyond ChREBP not examined
   • Potential therapeutic window for KCTD17 inhibition in metabolic disease not evaluated
7. 2023 Medium

   KCTD17 was shown to degrade CHOP in preadipocytes, linking its E3 adaptor function to adipogenesis control—KCTD17 gain-of-function inhibits and loss-of-function promotes adipocyte differentiation.

   Evidence Co-immunoprecipitation, ubiquitination assay, gain/loss-of-function in preadipocytes

   PMID:36868076

   Open questions at the time

   • Single-lab finding; independent confirmation needed
   • Whether KCTD17 regulates CHOP in tissues other than adipose not tested
   • Degron on CHOP recognized by KCTD17 not mapped
8. 2023 Medium

   An E3-independent function of KCTD17 was uncovered: its C-terminus binds Gβγ subunits and blunts Gβγ-dependent sensitization of adenylyl cyclase 5, establishing KCTD17 as a modulator of GPCR–cAMP signaling distinct from its ubiquitin ligase adaptor role.

   Evidence Live-cell BRET, Co-IP, truncation mutant analysis, cAMP sensitization assay

   PMID:36736897

   Open questions at the time

   • Single-lab finding; functional significance in vivo not demonstrated
   • Whether Gβγ sequestration and Cul3-adaptor activities compete or cooperate is unknown
   • Physiological contexts where this signaling modulation is relevant remain unidentified
9. 2024 High

   KCTD17 was shown to promote hepatocellular carcinoma by degrading LZTR1, a Ras destabilizer; KCTD17-mediated LZTR1 destruction stabilizes Ras and activates proliferation/migration, positioning KCTD17 as an oncogenic driver in liver cancer.

   Evidence Co-IP/MS substrate identification, hepatocyte-specific KO mice with DEN-induced HCC, xenograft models, ASO treatment

   PMID:39098817

   Open questions at the time

   • Whether KCTD17-LZTR1 axis operates in cancers beyond HCC not explored
   • Degron on LZTR1 and regulatory signals promoting this degradation not identified
10. 2024 Medium

    Redundancy among KCTD2/5/17 in cell growth control and Gβ1 regulation was quantified: progressive triple KO produced the strongest growth and transcriptomic effects, and KCTD KO had opposite gene-expression signatures to GNB1 KO, clarifying functional overlap within this paralog family.

    Evidence Sequential CRISPR KO in HEK293 cells, cell growth assays, transcriptomics

    PMID:38732215

    Open questions at the time

    • KCTD17-specific versus shared contributions could not be fully resolved due to redundancy
    • Whether redundancy holds in differentiated tissues with distinct expression patterns is untested
11. 2025 Medium

    KCTD17 was identified as a driver of liver fibrosis in MASH through a novel pathway: it degrades Zbtb7b, reducing SERPINA3 secretion and thereby activating hepatic stellate cells via Par2/TGFβ signaling.

    Evidence KCTD17 depletion in dietary MASH rodent models, pharmacological inhibition, Zbtb7b ubiquitination and SERPINA3 secretion assays, stellate cell activation

    PMID:40744994

    Open questions at the time

    • Single-lab finding on a novel substrate; independent validation needed
    • Direct binding interface between KCTD17 and Zbtb7b not mapped
    • Whether KCTD17 targeting in fibrosis is therapeutically feasible is unexplored

• Key unresolved questions include: what structural features define KCTD17 substrate degrons, how the pentameric ring coordinates multi-substrate recognition, whether the Gβγ-binding and Cul3-adaptor functions are functionally coupled in vivo, and whether KCTD17 has non-redundant roles in the nervous system.
• No co-crystal structure of KCTD17 bound to any substrate
• No in vivo characterization of KCTD17-specific neural functions
• Substrate selection logic across diverse degrons remains undefined